Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III OVF (fentanyl) for breakthrough cancer pain in opioid-tolerant patients
jRCT2080221194Phase 3
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Aug 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cancer pain and breakthrough pain comparing OVF (fentanyl) with Placebo (2 arms).
02
Drugs
fentanyl
03
Conditions
cancer painbreakthrough pain
Beyond the preview
Go deeper on jRCT2080221194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221194.